Attune Pharmaceuticals, Inc. announces the completion of a $23 million Series B financing with the proceeds to be used to advance a pipeline including the ongoing clinical development of ATN-249, a novel orally-administered plasma kallikrein inhibitor for the treatment of HAE.
Andrew McDonald, Ph.D., CEO of Attune, said, “This financing brings together a syndicate of investors with a deep understanding and long history of supporting companies that develop novel HAE therapeutics. Building upon our recently announced positive Phase 1 data, the Series B enables Attune to rapidly advance our lead clinical program through Phase 2 while also providing capital for our other pre-clinical discovery programs.”
ATN-249 is an oral, novel small molecule kallikrein inhibitor that was optimized for potency and pharmacokinetics. ATN-249 has been tested in phase 1 studies, where 249 achieved high blood levels and was shown to be safe and well-tolerated. In the phase 1 study, ATN-249 was shown to inhibit plasma kallikrein in vivo at levels that are expected to result in inhibition of HAE episodes.